Literature DB >> 16425485

HIV international clinical research: exploitation and risk.

Angela Ballantyne1.   

Abstract

This paper aims to show that to reduce the level of exploitation present in (some) international clinical trials, research sponsors must aim to provide both an ex-ante expected gain in utility and a fair ex-post distribution of benefits for research subjects. I suggest the following principles of fair risk distribution in international research as the basis of a normative definition of fairness: (a) Persons should not be forced (by circumstance) to gamble in order to achieve or protect basic goods; (b) In cases where one party is gambling with basic goods and the other party is not, the distribution of benefits and burdens must be arranged so that they are of greatest benefit to the worst off; (c) In relationships where one party is gambling for basic goods and the other party is not, the party gambling for basic goods must be assured of some guaranteed benefits in addition to the chance of getting some practical benefits. These principles are applied to the case of HIV international research. I conclude that the research (as described) is mutually advantageous but still exploitative because the distribution of surplus benefits is unfair. It is unfair because research subjects are gambling with and for basic goods but they are not assured of a fair ex-post distribution of benefits. Principles (b) and (c) are not satisfied. Research participants are not accorded enough guaranteed benefits to outweigh the risks they undertake.

Entities:  

Keywords:  Analytical Approach; Biomedical and Behavioral Research

Mesh:

Substances:

Year:  2005        PMID: 16425485     DOI: 10.1111/j.1467-8519.2005.00459.x

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  9 in total

1.  Sharing benefits in international health research. Research-capacity building as an example of an indirect collective benefit.

Authors:  Annette Schulz-Baldes; Effy Vayena; Nikola Biller-Andorno
Journal:  EMBO Rep       Date:  2007-01       Impact factor: 8.807

Review 2.  Human dignity as a basis for providing post-trial access to healthcare for research participants: a South African perspective.

Authors:  Pamela Andanda; Jane Wathuta
Journal:  Med Health Care Philos       Date:  2018-03

3.  Global bioethics: did the universal declaration on bioethics and human rights miss the boat?

Authors:  Cheryl Cox Macpherson
Journal:  J Med Ethics       Date:  2007-10       Impact factor: 2.903

4.  Decisional Capacity among Minors with HIV: A Model for Balancing Autonomy Rights with the Need for Protection.

Authors:  Tiffany Chenneville; Kimberly Sibille; Debra Bendell-Estroff
Journal:  Ethics Behav       Date:  2010-03-19

5.  Forms of benefit sharing in global health research undertaken in resource poor settings: a qualitative study of stakeholders' views in Kenya.

Authors:  Geoffrey M Lairumbi; Michael Parker; Raymond Fitzpatrick; Michael C English
Journal:  Philos Ethics Humanit Med       Date:  2012-01-17       Impact factor: 2.464

6.  Reasons Why Post-Trial Access to Trial Drugs Should, or Need not be Ensured to Research Participants: A Systematic Review.

Authors:  Neema Sofaer; Daniel Strech
Journal:  Public Health Ethics       Date:  2011-07-11       Impact factor: 1.940

7.  Benefit sharing: an exploration on the contextual discourse of a changing concept.

Authors:  Bege Dauda; Kris Dierickx
Journal:  BMC Med Ethics       Date:  2013-09-12       Impact factor: 2.652

Review 8.  Reviewing fair subject selection considerations for the unique case of post sequelae COVID-19 translational studies.

Authors:  E M Smith; E E Anderson; R Deer; J Prochaska; K Bohn; S Croisant
Journal:  J Clin Transl Sci       Date:  2022-07-07

9.  African HIV/AIDS trials are more likely to report adequate allocation concealment and random generation than North American trials.

Authors:  Nandi Siegfried; Michael Clarke; Jimmy Volmink; Lize Van der Merwe
Journal:  PLoS One       Date:  2008-10-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.